Newsletter - Banner

Breadcrumb

Asset Publisher

New study of therapy options in metastatic melanoma

RI-MUHC researchers lead “real-world” analysis of treatment patterns with checkpoint inhibitors

Nip it in the bud: New study will attack SARS-Cov2 where it multiplies

RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening

Serious Flaws in Studies Linking COVID-19 and Air Pollution

Studies have yet to prove this link, say Carleton and McGill University epidemiologists

Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach

In a new cost-analysis study, researchers recommend widespread testing of priority groups, including healthcare workers, school students and staff...

Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19

Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations

COVID-19 Q&A on dealing with pandemic fatigue

“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley

New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk

RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study

Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide

Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet

Inappropriate prescriptions sending hospitalized seniors back to the ER

Improving hospital prescribing practices may reduce risk of rehospitalization and death

Study identifies strategies to reduce breast cancer growth and related skeletal lesions

RI-MUHC team publishes findings in the journal, Bone Research

Early treatment trial of hydroxychloroquine shows no symptomatic benefit for COVID-19 patients

Adult outpatients with mild symptoms of COVID-19 don’t benefit from taking hydroxychloroquine

Sodium found to regulate the biological clock of mice

New study by RI-MUHC researchers first to establish that physiological signals influence circadian rhythms

At the heart of precision medicine

New translational collaboration aims to transform approach to heart muscle disease

Novel gene therapy trial offers hope to patients with rare metabolic disease

Samuel is the first Canadian and the ninth patient worldwide to participate in the second phase of a study using gene therapy to treat Glycogen storage...

Call for Applications: Executive Director and Chief Scientific Officer, Research Institute of the McGill University Health Centre (RI-MUHC)

The RI-MUHC is seeking a dynamic and strategic leader to serve as its next Executive Director and Chief Scientific Officer (ED/CSO)

Interdisciplinary Consortium Receives Grant to Develop Next-Generation Cell-Based Cancer Vaccines

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers

COVID-19 pandemic: Looking back to better tackle future challenges

In two recent studies, RI-MUHC researchers provide useful information for evaluating public health strategies

Canadian researchers work together to develop made-in-Canada COVID-19 testing capacity

The road towards Canadian testing capacity began in Montreal

Rifampin for Latent TB: Shorter and safer than the standard treatment, but also cheaper

A new study shows that rifampin regimen is cheaper than isoniazid for latent tuberculosis

See Archive - What's New